March 1, 2005Journal of Clinical OncologyOpen Access

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

View Full Paper

Ask AI

Bookmark

Why the study?

Does adding trastuzumab to neoadjuvant chemotherapy improve pathologic complete response in patients with HER2-positive operable breast cancer?

Structured PICO

Does adding trastuzumab to neoadjuvant chemotherapy improve pathologic complete response in patients with HER2-positive operable breast cancer?

Population

42 patients with human epidermal growth factor receptor 2 (HER2)-positive operable breast cancer

Intervention

Four cycles of paclitaxel followed by four cycles of fluorouracil, epirubicin, and cyclophosphamide with simultaneous weekly trastuzumab for 24 weeks

Comparator

Four cycles of paclitaxel followed by four cycles of fluorouracil, epirubicin, and cyclophosphamide

Outcome

Pathologic complete response (pCR) ratesurrogate

Adding trastuzumab to neoadjuvant chemotherapy significantly increases pathologic complete response rates in HER2-positive operable breast cancer without inducing clinical congestive heart failure.

Limitations

small sample size

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports adding trastuzumab to neoadjuvant chemotherapy for HER2-positive operable breast cancer; extends randomized evidence for improved responses.

Cite This Study

Buzdar et al. (2005) studied this question.

synapsesocial.com/papers/6a0fbf3092676d5461fd091f https://doi.org/10.1200/jco.2005.07.032

View Full Paper

Ask AI

Bookmark

Implication

Supports adding trastuzumab to neoadjuvant chemotherapy for HER2-positive operable breast cancer; extends randomized evidence for improved responses.

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider